Abstracts Archive - Page 2361 of 2425 - ACR Meeting Abstracts

Abstract Number: 933 • 2012 ACR/ARHP Annual Meeting
Economic Burden of Systemic Lupus Erythematosus by Flare Severity in a Commercially Insured Population in the United States
Siva Narayanan¹, Emily Durden², Alan Oglesby³, Paul Juneau⁴ and Kathleen L. Wilson⁵, ¹Global Health Economics and Outcomes Research and Epidemiology, Human Genome Sciences, Inc., Rockville, MD, ²Thomson Reuters, Austin, TX, ³GlaxoSmithKline, Research Triangle Park, NC, ⁴Truven Health Analytics, Washington, DC, ⁵Thomson Reuters Healthcare, Cambridge, MA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with an unpredictable disease course with sporadic periods of illness (flares). Little is known about…
Abstract Number: 894 • 2012 ACR/ARHP Annual Meeting
Genetic Variants in the IL-4 and IL-4 Receptor Genes in Association with the Severity of Joint Damage in Rheumatoid Arthritis: A Study in Seven Cohorts
A. Krabben¹, A. G. Wilson², R. Knevel¹, A. Zhernakova³, E. Brouwer³, E. Lindqvist⁴, T. Saxne⁴, G. Stoeken-Rijsbergen¹, J. A. B. van Nies¹, D. P. C. de Rooy¹, T.W.J. Huizinga¹, B. P. C. Koeleman⁵, R. E. M. Toes¹, P. K. Gregersen⁶ and A. H. M. van der Helm-van Mil¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, ³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, Netherlands, ⁴Rheumatology, Lund University, Lund, Sweden, ⁵Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Genomics and Human Genetics, Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY
Background/Purpose: The severity of RA is reflected by the severity of radiological joint destruction. It is highly variable between patients and up to 58% of…
Abstract Number: 895 • 2012 ACR/ARHP Annual Meeting
Transcriptomics of Synovial Tissue of Early Human (CHECK) and Experimental OA Identify Pathways Associated with Cartilage Damage
Arjen B. Blom¹, Peter L.E.M. van Lent², Martijn H. van den Bosch¹, Hans Cats³, Peter M. van der Kraan¹ and Wim B. van den Berg⁴, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology, Rheumatology Centre Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Many osteoarthritis (OA) patients show synovial inflammation, even relatively early during the disease. Mechanisms through which synovial activation contributes to the joint pathology that…
Abstract Number: 896 • 2012 ACR/ARHP Annual Meeting
Tyro3, Axl, MerTK-Receptor Activation by Gas6 or Pros1 Gene Delivery, ameliorates Collagen-induced arthritis
Fons A.J. van de Loo¹, Ben T. van Den Brand², Shahla Abdollahi-Roodsaz³, Eline A. Vermeij⁴, Miranda B. Bennink⁴, Onno J. Arntz⁵ and Wim B. van den Berg⁶, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Nijmegen, Netherlands, ⁶Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Insufficient controlled activation of innate immunity by cytokines and pattern recognition receptors could develop into auto-immune diseases. Stimulation of dendritic cells via the Axl receptor…
Abstract Number: 897 • 2012 ACR/ARHP Annual Meeting
IL-33 Promotes Mast Cell Survivial Via Inhibition of Apoptosis Associated with Enhanced Expression of Bcl-X_L
Shinjiro Kaieda¹, Jun-Xia Wang² and Peter A. Nigrovic³, ¹Department of Medicine, *Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, kurume, Japan, ²Department of Medicine, *Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Mast cells (MCs) are potent innate immune cells that frequently accumulate in chronically inflamed tissues, including the arthritic synovium. The factors that regulate MC…
Abstract Number: 898 • 2012 ACR/ARHP Annual Meeting
Nuclear Receptor Related 1 Induces Synovial Hyperplasia Via Transcriptional Regulation of Novel Target Genes
Kimberlee S. Mix, Biological Sciences, Loyola University New Orleans, New Orleans, LA
Background/Purpose: Nuclear receptor related 1 (NURR1 / NR4A2) is an orphan member of the nuclear receptor super-family that functions as a constitutively active transcription factor.…
Abstract Number: 899 • 2012 ACR/ARHP Annual Meeting
A Role for Soluble Interleukin-6 Receptor As an Antagonist of Interleukin-27 Signaling
Misato Hashizume¹, Keiko Esaki² and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Discovery Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Recently, it has been reported that interleukin (IL)-27 treatment reduces inflammation and ameliorates arthritis in collagen-induced arthritis mice. IL-27 is a heterodimeric cytokine composed…
Abstract Number: 900 • 2012 ACR/ARHP Annual Meeting
Deletion of RBP-J in a Murine Model of Inflammatory Arthritis Reveals Differential Pro-Inflammatory Cytokine and FoxP3 Gene Expression
Soumya D. Chakravarty¹, Karmen Au², Xiaoyu Hu³ and Lionel B. Ivashkiv⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Arthritis Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ⁴Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: The DNA-binding protein RBP-J serves as the central transcriptional regulator of the Notch signaling pathway. Prior work done using a knockdown approach of RBP-J…
Abstract Number: 901 • 2012 ACR/ARHP Annual Meeting
Colony-Stimulating Factor (CSF) Receptor 1 Blockade Overcomes Overlapping Effects of M-CSF and Interleukin-34 On Myeloid Differentiation and Gene Expression to Reduce Inflammation in Human and Murine Models of Rheumatoid Arthritis
Samuel Garcia¹, Linda M. Hartkamp², Inge E. van Es², Haishan Lin³, Li Long³, Emma L. Masteller³, Brian R. Wong³, Paul P. Tak⁴ and Kris A. Reedquist², ¹Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Five Prime Therapeutics, Inc., South San Francisco, CA, ⁴Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: Disease activity and response to therapy in RA correlates with changes in synovial macrophage numbers and their products. M-CSF or IL-34 stimulation of their…
Abstract Number: 902 • 2012 ACR/ARHP Annual Meeting
Activation of NF-Kb Via Poly(I:C)-Induced Monocyte-Derived Microparticles Decreases TRAIL-Induced Apoptosis of Rheumatoid Arthritis Synovial Fibroblasts
Mojca Frank Bertoncelj¹, Blaz Rozman², Beat A. Michel³, Renate E. Gay¹, David S. Pisetsky⁴, Oliver Distler⁵, Steffen Gay⁶ and Astrid Juengel⁷, ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ²Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Medicine, Duke University Medical Center, Durham, NC, ⁵Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁶Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, CH-8091, Switzerland, ⁷Center of Experimental Rheumatology, University Hospital Zurich, Zurich Schlieren, Switzerland
Background/Purpose: Decreased sensitivity of rheumatoid arthritis (RA) synovial fibroblasts (SF) to apoptosis leads to synovial hyperplasia and destruction of joints in RA. Activation of NF-kB…
Abstract Number: 903 • 2012 ACR/ARHP Annual Meeting
NR4A1 Mediates Anti-Inflammatory Effects of Apoptotic Cells
Natacha Ipseiz¹, Stefan Uderhardt¹, Georg A. Schett² and Gerhard Kronke¹, ¹Internal Medicine 3, University of Erlangen, Erlangen, Germany, ²Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: The nuclear receptor NR4A1 has been implicated as negative feedback regulator of NF kappa B signalling and as key regulator during the differentiation of…
Abstract Number: 904 • 2012 ACR/ARHP Annual Meeting
Perinatal Characteristics, Maternal Reproductive History and Juvenile Idiopathic Arthritis: A Case-Control Study
Samantha W. Bell¹, Beth A. Mueller¹, J. Lee Nelson², Parveen Bhatti¹ and Susan Shenoi³, ¹Epidemiology and Public Health, University of Washington, Seattle, WA, ²Immunogenetics D2-100, Fred Hutchinson Cancer Rsch, Seattle, WA, ³Pediatric Rheumatology, Seattle Children's Hospital, University of Washington, Seattle, WA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of chronic inflammatory arthritis conditions in children with onset before 16 years of age, and is the…
Abstract Number: 905 • 2012 ACR/ARHP Annual Meeting
The Association Between Lower Body Mass Index and Increased Risk of Giant Cell Arteritis Is Not Explained by Differences in Physical Activity
Karin Jakobsson¹, Lennart T.H. Jacobsson¹, Kenneth J. Warrington², Eric L. Matteson³, Kimberly P. Liang⁴, Olle Melander⁵ and Carl Turesson¹, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Unit of Hypertension and Cardiovascular Disease, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: There is limited data on predictors of giant cell arteritis (GCA). Low body mass index (BMI), a history of smoking and several hormonal factors…
Abstract Number: 906 • 2012 ACR/ARHP Annual Meeting
Patient-Rheumatologist Communication Concerning Medication and Disease Risks
Susan J. Blalock, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Medications play an important role in the management of rheumatoid arthritis. Principles of informed consent, informed and shared decision-making, and professional ethics highlight the importance…
Abstract Number: 907 • 2012 ACR/ARHP Annual Meeting
Use of Patient Preferences to Inform the Development of Disease Modifying Drugs for Osteoarthritis
Liana Fraenkel¹, Charles Cunningham², Gillian A. Hawker³ and Lisa Suter⁴, ¹Medicine, Section of Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, ²McMaster University, Hamilton, ON, Canada, ³Women's College Research Institute, University of Toronto, Toronto, ON, Canada, ⁴Medicine, Rheumatol, TAC S541, Yale University, New Haven, CT
Background/Purpose: Considerable efforts are currently being directed at developing robust and efficient trial designs to study the efficacy of disease modifying drugs (DMOADs) for osteoarthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].